Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 2Cardiotoxicity 2Breast Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peripheral Nervous System Diseases 1Leukemia 1Gastrointestinal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Cognitive Dysfunction 1

Interventions

Cyclophosphamide 413Methotrexate 250Cytarabine 235Vincristine 192fludarabine phosphate 174Dexamethasone 171fludarabine 147Etoposide 143Peripheral Blood Stem Cell Transplantation 137Filgrastim 132Whole-Body Irradiation 118Mycophenolic Acid 116Busulfan 113Doxorubicin 110Mercaptopurine 108Tacrolimus 107Cyclosporine 95Radiotherapy 93Melphalan 93pegaspargase 90Rituximab 90Prednisone 87Asparaginase 87Daunorubicin 86Granulocyte Colony-Stimulating Factor 76blinatumomab 74Antilymphocyte Serum 71Calcium Dobesilate 69Clofarabine 58Thiotepa 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Silymarin × Clear all
NCT00055718 2013-12-18

Silymarin (Milk Thistle Extract) in Treating Patients With Acute Lymphoblastic Leukemia Who Are Receiving Chemotherapy

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡